{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.3","upperLimit":"22.7","value":"19.5"},{"groupId":"OG001","lowerLimit":"10.0","upperLimit":"16.4","value":"13.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Velcade (Bortezomib)\n\nThalidomide\n\nDexamethasone","id":"OG000","title":"Thal + Dex + Velcade"},{"description":"Standard treatment\n\nThalidomide\n\nDexamethasone","id":"OG001","title":"Thal + Dex"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 year","title":"Median Time to Progression (TTP)","type":"PRIMARY","unitOfMeasure":"months"}